Fitzgerald Thomas A Insider Trades

Insider Trading History

Track insider trading activity for Fitzgerald Thomas A. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
TransCode Therapeutics
TransCode Therapeutics RNAZ
Interim Ceo, CFO
Holding Value $3.8M 650,000 shares
Last Trade
Jun 14, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$505M 650,000 shares
$776.16
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Chief Financial Officer
Holding Value $329k 56,318 shares
Last Trade
Sep 28, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$734M 49,350 shares
$14,880.32
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Chief Financial Officer
Holding Value $1.75M 300,000 shares
Last Trade
May 19, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$44.1B 300,000 shares
$147,156.80
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Chief Financial Officer
Holding Value $584k 100,000 shares
Last Trade
Dec 12, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$26.4B 100,000 shares
$263,894.40
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Chief Financial Officer
Holding Value $814k 139,377 shares
Last Trade
Jun 16, 2022 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$7.82B 12,000 shares
$651,974.40
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Chief Financial Officer
Holding Value $304k 52,000 shares
Last Trade
Mar 01, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$57B 52,000 shares
$1,096,972.80
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Chief Financial Officer
Holding Value $193k 33,000 shares
Last Trade
Feb 01, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$41.8B 33,000 shares
$1,267,673.12
$5.84
TransCode Therapeutics
TransCode Therapeutics RNAZ
Vp, Chief Financial Officer
Holding Value $744k 127,377 shares
Last Trade
Jul 08, 2021 Sale
No data
No data
$5.84

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up